@2024 - All Right Reserved.
Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback